Snubbed, Miraculins Withdraws Offer to Acquire IBEX

Dec 14, 2006

NEW YORK (GenomeWeb News) — Canadian biomarker company Miraculins has withdrawn its offer to acquire diagnostics developer IBEX technologies.

In mid-November Winnipeg-based Miraculins made an unsolicited offer to acquire IBEX through a stock deal that would exchange one common Miraculins share for five shares in IBEX.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

NIH's Collins on Harassment

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

With Eight Arms and Giant Eyes

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Missing From Trials

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

This Week in Cell

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.

Main menu